Join
Live feed
·
PRReleasevia Quantisnow
Exelixis Inc. logo

Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer

ByQuantisnow·Wall Street's wire, on your screen.
EXEL· Exelixis Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EXEL (Exelixis Inc.) and more on Quantisnow.